Percent expression of dominant apo(a) isoform

1. Olpasiran has no effect on percent expression of dominant apo(a) isoform in humans (+1.1 [±9.8] % with olpasiran and +2.1 [±12.8] % with placebo, p = 0.65).

   “No significant change was observed over time in the percent expression of the dominant apo(a) isoform with olpasiran compared to placebo”

   Human trialover 36 weeks compared to placebo36 weeks

   Efficacy of Olpasiran by Apolipoprotein(a) Isoform Size: Insights from the OCEAN(a)-DOSE Trial

   AHA Scientific Sessions 2025 abstract·3 Nov 2025

More on Olpasiran